[Clinical observation of ZD1839 in treating 32 cases of non-small-cell lung cancer].
To study e the therapeutic and adverse effects of ZD1839 in treating non-small-cell lung cancer (NSCLC). The therapeutic and adverse effects of ZD1839 given orally were observed in 32 NSCLC cases after a treatment course more than 90 d. The rates of complete remission (CR), partial remission (PR), and stabilization (SD) were 0%, 18.75%, and 37.50% respectively, with a disease control rate of 56.25%. The adverse effects of this agent included acneiform rash, diarrhea, aminotransferase elevation, nausea and vomiting, occurring in 31.25%, 18.75%, 12.50% and 15.63% of the cases respectively. No interstitial lung disease was found. ZD1839 is a new drug producing acceptable disease control rate along with tolerable adverse effects in patients with lung cancer.